Health Care [ 12/12 ] | Pharmaceuticals [ 64/74 ]
NYSE | Common Stock
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally.
It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.
The Salix segment provides gastroenterology products in the United States.
The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally.
The Solta Medical segment engages in the sale of aesthetic medical devices.
The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States.
The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products.
The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018.
Bausch Health Companies Inc. is headquartered in Laval, Canada.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 1, 24 | 0.03 Decreased by -96.71% | 0.88 Decreased by -96.93% |
| May 2, 24 | 0.60 Increased by +15.38% | 0.72 Decreased by -16.67% |
| Feb 22, 24 | 1.15 Increased by +11.65% | 1.02 Increased by +12.75% |
| Nov 2, 23 | 1.02 Increased by +34.21% | 0.92 Increased by +10.87% |
| Aug 3, 23 | 0.82 Increased by +46.43% | 0.78 Increased by +5.13% |
| May 4, 23 | 0.52 Decreased by -28.77% | 0.72 Decreased by -27.78% |
| Feb 23, 23 | 1.03 Decreased by -19.53% | 0.91 Increased by +13.19% |
| Nov 3, 22 | 0.76 Decreased by -34.48% | 0.84 Decreased by -9.52% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 2.51 B Increased by +12.15% | -85.00 M Increased by +77.51% | Decreased by -3.39% Increased by +79.95% |
| Jun 30, 24 | 2.40 B Increased by +10.87% | 10.00 M Decreased by -61.54% | Increased by +0.42% Decreased by -65.31% |
| Mar 31, 24 | 2.14 B Increased by +10.26% | -63.71 M Increased by +69.51% | Decreased by -2.97% Increased by +72.35% |
| Dec 31, 23 | 2.41 B Increased by +9.80% | 395.00 M Increased by +196.34% | Increased by +16.40% Increased by +187.74% |
| Sep 30, 23 | 2.24 B Increased by +9.38% | -378.00 M Decreased by -194.74% | Decreased by -16.89% Decreased by -186.61% |
| Jun 30, 23 | 2.17 B Increased by +10.17% | 26.00 M Increased by +118.71% | Increased by +1.20% Increased by +116.98% |
| Mar 31, 23 | 1.94 B Increased by +1.36% | -209.00 M Decreased by -216.67% | Decreased by -10.75% Decreased by -212.43% |
| Dec 31, 22 | 2.19 B Decreased by -0.14% | -410.00 M Decreased by -694.20% | Decreased by -18.70% Decreased by -695.02% |